GB2088877B - Androstane 17 carbothioates - Google Patents

Androstane 17 carbothioates

Info

Publication number: GB2088877B
Authority: GB; United Kingdom
Prior art keywords: carbothioates; androstane
Prior art date: 1980-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

GB8104496A

Other versions

GB2088877A (en

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-02-15

Filing date

1981-02-13

Publication date

1984-07-04

1981-02-13 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1981-02-13 Priority to GB8104496A priority Critical patent/GB2088877B/en

1981-02-13 Priority to CY129181A priority patent/CY1291A/en

1982-06-16 Publication of GB2088877A publication Critical patent/GB2088877A/en

1984-07-04 Application granted granted Critical

1984-07-04 Publication of GB2088877B publication Critical patent/GB2088877B/en

Status Expired legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Steroid Compounds (AREA)

GB8104496A 1980-02-15 1981-02-13 Androstane 17 carbothioates Expired GB2088877B (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GB8104496A GB2088877B (en)	1980-02-15	1981-02-13	Androstane 17 carbothioates
CY129181A CY1291A (en)	1980-02-15	1981-02-13	Androstane 17 beta carbothioates

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8005174		1980-02-15
GB8104496A GB2088877B (en)	1980-02-15	1981-02-13	Androstane 17 carbothioates

Publications (2)

Publication Number	Publication Date
GB2088877A GB2088877A (en)	1982-06-16
GB2088877B true GB2088877B (en)	1984-07-04

Family

ID=26274506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB8104496A Expired GB2088877B (en)	1980-02-15	1981-02-13	Androstane 17 carbothioates

Country Status (2)

Country	Link
CY (1)	CY1291A (en)
GB (1)	GB2088877B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002012266A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6536427B2 (en)	1990-03-02	2003-03-25	Glaxo Group Limited	Inhalation device
US6792945B2 (en)	1990-03-02	2004-09-21	Glaxo Group Limited	Inhalation device
EP2039700A2 (en)	2001-04-30	2009-03-25	Glaxo Group Limited	Novel anti-inflammatory androstane derivatives
US7531528B2 (en)	2000-08-05	2009-05-12	Glaxo Group Limited	Formulation containing anti-inflammatory androstane derivatives
EP2266590A2 (en)	2002-02-22	2010-12-29	Shire LLC	Active agent delivery sytems and methods for protecting and administering active agents
EP2363121A1 (en)	2002-02-04	2011-09-07	Glaxo Group Limited	Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
US8163723B2 (en)	2002-06-14	2012-04-24	Cipla Limited	Combination of azelastine and steroids
US8969547B2 (en)	2010-12-14	2015-03-03	Zhejiang Tiantai Aurisco Pharmaceuticals Co. Ltd.	Method for preparing fluticasone furoate
EP3510994A1 (en)	2002-02-04	2019-07-17	Glaxo Group Limited	Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8630913D0 (en) *	1986-12-24	1987-02-04	Glaxo Group Ltd	Pharmaceutical compositions
US5270305A (en)	1989-09-08	1993-12-14	Glaxo Group Limited	Medicaments
DE69227257T2 (en)	1991-12-12	1999-03-25	Glaxo Group Ltd	DRUG
US5916540A (en)	1994-10-24	1999-06-29	Glaxo Group Limited	Aerosol formulations containing P134A and/or P227 and particulate medicament
IL104068A (en) †	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9622173D0 (en) *	1996-10-24	1996-12-18	Glaxo Group Ltd	Particulate Products
US20020133032A1 (en)	2000-02-25	2002-09-19	Jufang Barkalow	Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009606D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Therapeutic combinations
GB0009591D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Medical combinations
GB0017988D0 (en) *	2000-07-21	2000-09-13	Glaxo Group Ltd	Novel process
US6777399B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
WO2004001369A2 (en) *	2002-06-20	2003-12-31	Sun Pharmaceutical Industries Limited	Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
US20070270584A1 (en) *	2003-04-04	2007-11-22	Trond Loevli	Process for the Preparation of Steroidal Carbothioic Acid Derivatives and Intermediates
MXPA06001642A (en)	2003-08-11	2006-04-28	Glaxo Group Ltd	Pharmaceutical metered dose inhaler and methods relating thereto.
PT103202B (en)	2004-10-19	2011-01-27	Hovione Farmaciencia S A	PROCESS FOR THE ESTERIFICATION OF A CARBOOTHYTIC ACID
NZ555500A (en)	2004-12-17	2010-09-30	Cipla Ltd	Crystalline forms of levosalbutamol sulfate, process for their preparation, and their use in respiratory conditions
AU2013202843B2 (en) *	2006-06-14	2015-11-12	Generics [Uk] Limited	Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
WO2007144668A2 (en) *	2006-06-14	2007-12-21	Generics [Uk] Limited	Process for the preparation of s-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
WO2013009591A1 (en)	2011-07-08	2013-01-17	Pfizer Limited	Process for the preparation of fluticasone propionate form 1
US8765725B2 (en)	2012-05-08	2014-07-01	Aciex Therapeutics, Inc.	Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
HUE050993T2 (en)	2012-05-08	2021-01-28	Nicox Ophthalmics Inc	Polymorphic form of fluticasone propionate
US9815865B2 (en)	2013-01-07	2017-11-14	Nicox Ophthalmics, Inc.	Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP3047846A1 (en)	2015-01-22	2016-07-27	Ems S.A.	Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US9980975B2 (en)	2015-01-22	2018-05-29	Ems S.A.	Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus

1981
- 1981-02-13 GB GB8104496A patent/GB2088877B/en not_active Expired
- 1981-02-13 CY CY129181A patent/CY1291A/en unknown

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6536427B2 (en)	1990-03-02	2003-03-25	Glaxo Group Limited	Inhalation device
US6792945B2 (en)	1990-03-02	2004-09-21	Glaxo Group Limited	Inhalation device
EP2348032A2 (en)	2000-08-05	2011-07-27	Glaxo Group Limited	6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
EP1775305A2 (en)	2000-08-05	2007-04-18	Glaxo Group Limited	6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
US7531528B2 (en)	2000-08-05	2009-05-12	Glaxo Group Limited	Formulation containing anti-inflammatory androstane derivatives
EP2067784A2 (en)	2000-08-05	2009-06-10	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivates as anti-flammatory agents
WO2002012266A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
EP2039700A2 (en)	2001-04-30	2009-03-25	Glaxo Group Limited	Novel anti-inflammatory androstane derivatives
EP3510994A1 (en)	2002-02-04	2019-07-17	Glaxo Group Limited	Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
EP2363121A1 (en)	2002-02-04	2011-09-07	Glaxo Group Limited	Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
EP2316469A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
EP2266590A2 (en)	2002-02-22	2010-12-29	Shire LLC	Active agent delivery sytems and methods for protecting and administering active agents
US8163723B2 (en)	2002-06-14	2012-04-24	Cipla Limited	Combination of azelastine and steroids
US8168620B2 (en)	2002-06-14	2012-05-01	Cipla Limited	Combination of azelastine and steroids
US8304405B2 (en)	2002-06-14	2012-11-06	Cipla Limited	Combination of azelastine and ciclesonide for nasal administration
US8318709B2 (en)	2002-06-14	2012-11-27	Cipla Limited	Combination of azelastine and mometasone for nasal administration
US8969547B2 (en)	2010-12-14	2015-03-03	Zhejiang Tiantai Aurisco Pharmaceuticals Co. Ltd.	Method for preparing fluticasone furoate

Also Published As

Publication number	Publication date
GB2088877A (en)	1982-06-16
CY1291A (en)	1985-10-18

Publication	Publication Date	Title
GB2088877B (en)	1984-07-04	Androstane 17 carbothioates
ZA81976B (en)	1982-07-28	Androstane carbothioates
JPS56137996A (en)	1981-10-28	Note
CS697681A2 (en)	1985-08-15	Zpusob snizovani lomu taveniny vytvareneho v prubehu vytlacovan i roztaveneho linearniho ethylenoveho polymeru o uzke distribuci molekulove hmotnosti
MY8700055A (en)	1987-12-31	10 - alknyl steroids
JPS57189898A (en)	1982-11-22	Note
CS82782A2 (en)	1984-06-18	Zpusob odstranovani kyslicnikovych okuji z povrchu kovovych predmetu
GB8328569D0 (en)	1983-11-30	3 5-dinitrophthalimides
ZA814874B (en)	1982-08-25	N-phenylsulfonyl-n'-pyrimidinyl- and -triazinylureas
GB2103261B (en)	1985-08-21	Stage
JPS5754184A (en)	1982-03-31	Jiokisabishikuro 3 2 1 okutanruioyobiokisepanruinoseizohoho
JPS5754131A (en)	1982-03-31	4 t buchirutoruenruinosentakuharogenkahooyobisonoharogenkakongobutsu
JPS5747697A (en)	1982-03-18	Note
JPS56136395A (en)	1981-10-24	Note
JPS57152999A (en)	1982-09-21	Note
CS193681A1 (en)	1984-04-16	Dalkove ovladany regulacni sroub barvicich zarizeni v zasobnicich barev tiskovych stroju
ZA823782B (en)	1983-03-30	11 alpha-amino-androstanes
GB8427294D0 (en)	1984-12-05	1 3 2-dioxaphospholes
YU80481A (en)	1983-06-30	"self-securty"-protection-class arrangement
JPS56101898A (en)	1981-08-14	Note
JPS5754147A (en)	1982-03-31	Arukirupaafuruoro 4 77jiokisaa55mechiruu88furuorofuorumirunonanoeeto noseizoho
JPS57159698A (en)	1982-10-01	Note
JPS57165297A (en)	1982-10-12	Note
CS881280A1 (en)	1984-05-14	Zapojeni pro prenos nebo autonomni zaznam urovne skodlivin v ovzdusi
GR65697B (en)	1980-10-21	Improvement of the european bee-live

Legal Events

Date	Code	Title	Description
1993-07-28	CTFF	Supplementary protection certificate filed	Free format text: SPC/GB93/075, 930617
1993-11-24	CTFG	Supplementary protection certificate granted	Free format text: SPC/GB93/075, 931029, EXPIRES:20050307
2001-03-07	CTFE	Supplementary protection certificate entered into force	Free format text: SPC/GB93/075: 20010213, EXPIRES: 20050307
2001-03-07	PE20	Patent expired after termination of 20 years	Effective date: 20010212
2005-03-30	SPCE	Supplementary protection certificate expired	Free format text: SPC/GB93/075, EXPIRES: 20050307 Spc suppl protection certif: SPC/GB93/075 Expiry date: 20050307